NeuBase Therapeutics, Inc.: 10-Q filed 2019-08-14
What NeuBase Therapeutics, Inc. reported in its quarterly report filed 2019-08-14 (fiscal Q3 2019): 25 published measures, 71 facts as tagged in accession 0001387131-19-006165.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2019-08-14
- Fiscal period
- fiscal Q3 2019
- Accession
- 0001387131-19-006165 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All NeuBase Therapeutics, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-06-30 | 8,692,910 | USD | |
| At 2018-09-30 | 11,626,115 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-06-30 | 751,701 | USD | |
| At 2018-09-30 | 724,998 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-06-30 | 7,941,209 | USD | |
| At 2019-03-31 | 9,007,199 | USD | |
| At 2018-12-31 | 10,076,870 | USD | |
| At 2018-09-30 | 10,901,117 | USD | |
| At 2018-06-30 | 17,183,487 | USD | |
| At 2018-03-31 | 17,655,138 | USD | |
| At 2017-12-31 | 19,683,594 | USD | |
| At 2017-09-30 | 22,844,965 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-06-30 | 1,424,596 | USD | |
| At 2018-09-30 | 3,750,436 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-04-01 to 2019-06-30 | -1,132,975 | USD | 91 |
| 2018-10-01 to 2019-06-30 | -3,173,647 | USD | 273 |
| 2019-01-01 to 2019-03-31 | -1,143,048 | USD | 90 |
| 2018-10-01 to 2018-12-31 | -897,624 | USD | 92 |
| 2018-04-01 to 2018-06-30 | -545,028 | USD | 91 |
| 2017-10-01 to 2018-06-30 | -6,881,153 | USD | 273 |
| 2018-01-01 to 2018-03-31 | -2,184,767 | USD | 90 |
| 2017-10-01 to 2017-12-31 | -4,151,358 | USD | 92 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2019-06-30 | -2,248,554 | USD | 273 |
| 2017-10-01 to 2018-06-30 | -8,895,803 | USD | 273 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2019-06-30 | 4,069 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2019-06-30 | -73,217 | USD | 273 |
| 2017-10-01 to 2018-06-30 | 22,067 | USD | 273 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2019-06-30 | -4,069 | USD | 273 |
| 2017-10-01 to 2018-06-30 | 508,078 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-06-30 | -124,499,154 | USD | |
| At 2018-09-30 | -121,325,507 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-06-30 | 12,595 | USD | |
| At 2018-09-30 | 15,763 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2019-06-30 | 213,739 | USD | 273 |
| 2017-10-01 to 2018-06-30 | 804,374 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-04-01 to 2019-06-30 | -1,136,936 | USD | 91 |
| 2018-10-01 to 2019-06-30 | -3,196,189 | USD | 273 |
| 2018-04-01 to 2018-06-30 | -1,166,341 | USD | 91 |
| 2017-10-01 to 2018-06-30 | -7,532,852 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-06-30 | 1,558,097 | USD | |
| At 2018-09-30 | 3,998,434 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-06-30 | 751,701 | USD | |
| At 2018-09-30 | 724,998 | USD |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-06-30 | 7,122,218 | USD | |
| At 2018-09-30 | 7,611,918 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-04-01 to 2019-06-30 | 82,751 | USD | 91 |
| 2018-10-01 to 2019-06-30 | 235,289 | USD | 273 |
| 2018-04-01 to 2018-06-30 | 52,630 | USD | 91 |
| 2017-10-01 to 2018-06-30 | 4,242,307 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-06-30 | 2,829,248 | shares | |
| At 2018-09-30 | 2,829,248 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-06-30 | 132,440,080 | USD | |
| At 2018-09-30 | 132,226,341 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-04-01 to 2019-06-30 | 888,538 | USD | 91 |
| 2018-10-01 to 2019-06-30 | 2,463,964 | USD | 273 |
| 2018-04-01 to 2018-06-30 | 834,703 | USD | 91 |
| 2017-10-01 to 2018-06-30 | 2,935,919 | USD | 273 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2019-06-30 | 7,236 | USD | 273 |
| 2017-10-01 to 2018-06-30 | 7,877 | USD | 273 |
Amortization of intangible assets
Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-04-01 to 2019-06-30 | 163,234 | USD | 91 |
| 2018-10-01 to 2019-06-30 | 489,701 | USD | 273 |
| 2018-04-01 to 2018-06-30 | 276,667 | USD | 91 |
| 2017-10-01 to 2018-06-30 | 834,642 | USD | 273 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-04-01 to 2018-06-30 | 610,383 | USD | 91 |
| 2017-10-01 to 2018-06-30 | 592,584 | USD | 273 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-04-01 to 2019-06-30 | 3,961 | USD | 91 |
| 2018-10-01 to 2019-06-30 | 22,542 | USD | 273 |
| 2018-04-01 to 2018-06-30 | 621,313 | USD | 91 |
| 2017-10-01 to 2018-06-30 | 651,699 | USD | 273 |
Interest paid, net
Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-10-01 to 2019-06-30 | 779 | USD | 273 |
| 2017-10-01 to 2018-06-30 | 7,540 | USD | 273 |
Inspect the source
- Entity
- NeuBase Therapeutics, Inc. / CIK 0001173281
- Captured
- SEC response SHA-256
0e0882fa147fcb0a3e5f3af54573abe947d9ade4d42095debd16c2d62da36e79
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001173281.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))